- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Incyte Corporation (INCY)
The Incyte share price today is 119.52, view NASDAQ INCY stock exchange data. Track the latest Incyte share price with real-time updates on INCY stock performance including market cap, day range, 52-week range and dividend yield. Access INCY charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
118.44
122.75
52 wk Range
75.48
132.60
INCY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
118.44122.75
52 wk Range
75.48132.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INCY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
122.96
Upside
+2.88%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
12 analysts have revised their earnings downwards for the upcoming period
Incyte Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Incyte Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Incyte Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
11 Buy
15 Hold
1 Sell
Ratings:
27 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 122.96
(+2.88% Upside)
Incyte Corporation SWOT Analysis
Patent Cliff Looms | Incyte faces a $3 billion patent cliff by 2029, primarily due to Jakafi's loss of exclusivity, driving urgent need for new revenue streams |
Pipeline Progress | Explore Incyte's diverse pipeline, including promising drugs like povorcitinib, with potential to generate $600 million in hidradenitis suppurativa alone |
Market Valuation | Analyst consensus maintains a moderate buy, with price targets ranging from $52 to $96, reflecting varied views on Incyte's growth potential |
Strategic Expansion | Learn about Incyte's ambitious plan to launch ten new products by 2030, aiming to offset Jakafi's patent expiration and diversify revenue |
Incyte Corporation Earnings Call Summary for Q2/2026
- Incyte Q2 2026 EPS of $3.09 beat estimates of $1.99 by 55%; revenue of $1.67B topped forecasts of $1.42B by 17.6%, aided by $246M CMS settlement.
- Full-year 2026 sales guidance raised to $5.13B-$5.26B from $4.8B-$4.9B; OPZELURA guidance increased to $1.05B-$1.10B from $750M-$790M.
- Jakafi sales grew 7% YoY to $817M; total net product sales rose 40% to $1.49B, with underlying growth of 17% excluding settlement benefit.
- CEO emphasized strategic shift from single-product dependence to diversified platform with multiple growth drivers and late-stage pipeline assets.
- Shares rose 0.11% to $119 in premarket, near 52-week high of $120.71; upcoming catalysts include European OPZELURA decision and pipeline readouts.
Last Updated: 28-07-2026, 06:50 pm
Read Full TranscriptEarnings
Latest Release
28-07-2026
EPS / Forecast
3.09 / 1.99
Revenue / Forecast
1.67B / 1.42B
Compare INCY to Peers and Sector
Metrics to compare | INCY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINCYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 15.0x | −5.8x | −0.4x | |
PEG Ratio | 0.19 | 0.15 | 0.00 | |
Price/Book | 3.8x | 1.3x | 2.6x | |
Price / LTM Sales | 4.2x | 1.8x | 3.0x | |
Upside (Analyst Target) | 0.4% | 62.4% | 56.0% | |
Fair Value Upside | Unlock | −5.9% | 9.1% | Unlock |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Incyte (INCY) Share Price Today?
The Incyte share price today is 119.52.
What is the current Incyte (INCY) share price and day range?
As of 03-08-2026, the Incyte share price is 119.52, with a previous close of 119.52. The share price has ranged from 118.44 to 122.75 today, while the 52-week range spans from 75.48 to 132.60.
What Is the Incyte Market Cap?
As of today, Incyte market cap is 24.23B.
What Is the Incyte (INCY) Share Price Target?
The average 12-month share price target for Incyte is 122.96, with a high estimate of 150 and a low estimate of 86. 11 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +2.88% Upside potential.
What Is Incyte's Earnings Per Share (TTM)?
The Incyte EPS (TTM) is 7.85.
When Is the Next Incyte Earnings Date?
Incyte will release its next earnings report on 03-11-2026.
From a Technical Analysis Perspective, Is INCY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
What Stock Exchange Does Incyte Trade On?
Incyte is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Incyte?
The stock symbol for Incyte is "INCY."
How Many Times Has Incyte Stock Split?
Incyte has split 2 times.
How Many Employees Does Incyte Have?
Incyte has 2844 employees.
What Is the INCY Premarket Price?
INCY's last pre-market stock price is 119.95. The pre-market share volume is 340.00, and the stock has changed by 0.43, or 0.36%.
What Is the INCY After Hours Price?
INCY's last after hours stock price is 117.75, the stock has changed by -1.77, or -1.48%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.